|Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function|
S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ...
Cancer research 68 (3), 826-833, 2008
|TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer|
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
|A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models|
X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ...
Cancer research 73 (15), 4885-4897, 2013
|Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2 …|
B Dave, I Migliaccio, MC Gutierrez, MF Wu, GC Chamness, H Wong, ...
Journal of Clinical Oncology 29 (2), 166, 2011
|Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation|
YC Wang, G Morrison, R Gillihan, J Guo, RM Ward, X Fu, MF Botero, ...
Breast Cancer Research 13 (6), 1-19, 2011
|Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 …|
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ...
Journal of clinical oncology 31 (14), 1726, 2013
|Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy|
G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ...
Journal of the National Cancer Institute 99 (9), 694-705, 2007
|Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes|
MF Rimawi, PB Shetty, HL Weiss, R Schiff, CK Osborne, GC Chamness, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
|Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/neu-positive breast cancer|
S Massarweh, CK Osborne, S Jiang, AE Wakeling, M Rimawi, SK Mohsin, ...
Cancer research 66 (16), 8266-8273, 2006
|Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators|
R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ...
Cancer chemotherapy and pharmacology 56 (1), 10-20, 2005
|Targeting HER2 for the treatment of breast cancer|
MF Rimawi, R Schiff, CK Osborne
Annual review of medicine 66, 2015
|Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial|
S Aebi, S Gelber, SJ Anderson, I Láng, A Robidoux, M Martín, ...
The lancet oncology 15 (2), 156-163, 2014
|β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib|
C Huang, CC Park, SG Hilsenbeck, R Ward, MF Rimawi, Y Wang, J Shou, ...
Breast cancer research 13 (4), 1-15, 2011
|Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial|
J Nangia, T Wang, C Osborne, P Niravath, K Otte, S Papish, F Holmes, ...
Jama 317 (6), 596-605, 2017
|High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti–IGF-IR therapy|
BC Litzenburger, CJ Creighton, A Tsimelzon, BT Chan, SG Hilsenbeck, ...
Clinical Cancer Research 17 (8), 2314-2327, 2011
|Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up|
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136 (3), 795-804, 2012
|Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2–positive breast cancer and …|
RA Freedman, RS Gelman, JS Wefel, ME Melisko, KR Hess, RM Connolly, ...
Journal of Clinical Oncology 34 (9), 945, 2016
|TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases|
RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ...
Journal of Clinical Oncology 37 (13), 1081, 2019
|Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts|
MF Rimawi, LS Wiechmann, YC Wang, C Huang, I Migliaccio, MF Wu, ...
Clinical Cancer Research 17 (6), 1351-1361, 2011
|Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon e in women with hormone receptor–negative breast cancer|
KD Crew, P Brown, H Greenlee, TB Bevers, B Arun, C Hudis, HL McArthur, ...
Cancer prevention research 5 (9), 1144-1154, 2012